nivolumab

• 

ASCO GU 2023: A triple combination for previously untreated kidney cancer patients

By Sharon Deveson Kell|2023-03-07T14:33:29+00:007 Mar 2023|Drug treatments|

At the American Society of  Clinical Oncology Genitourinary Cancers Conference [...]

Read More

Comments Off on ASCO GU 2023: A triple combination for previously untreated kidney cancer patients

• 

ASCO GU 2023: Treatment-free survival for advanced kidney cancer patients on nivolumab and salvage nivolumab/ipilimumab

By Sharon Deveson Kell|2023-03-06T14:59:34+00:006 Mar 2023|Drug treatments|

In this study presented at the American Society of Clinical [...]

Read More

Comments Off on ASCO GU 2023: Treatment-free survival for advanced kidney cancer patients on nivolumab and salvage nivolumab/ipilimumab

• 

Adjuvant nivolumab plus ipilimumab in localised kidney cancer

By Sharon Deveson Kell|2023-02-27T10:20:33+00:0027 Feb 2023|Drug treatments|

A recent phase 3 study called CheckMate 914 has shown [...]

Read More

Comments Off on Adjuvant nivolumab plus ipilimumab in localised kidney cancer

• 

ASCO GU 2023: Further information from the cabozantinib plus nivolumab study

By Sharon Deveson Kell|2023-02-23T14:39:48+00:0023 Feb 2023|Drug treatments|

At the American Society of  Clinical Oncology Genitourinary Cancers Conference [...]

Read More

Comments Off on ASCO GU 2023: Further information from the cabozantinib plus nivolumab study

• 

Does neoadjuvant therapy improve outcomes in localised kidney cancer?

By Sharon Deveson Kell|2023-01-12T09:51:58+00:0012 Jan 2023|Drug treatments|

At the 2023 Society of Urologic Oncology (SUO) Annual Meeting, [...]

Read More

Comments Off on Does neoadjuvant therapy improve outcomes in localised kidney cancer?

• 

Nivolumab plus ipilimumab for advanced kidney cancer after progression on immunotherapy

By Sharon Deveson Kell|2022-11-15T09:09:15+00:0015 Nov 2022|Drug treatments|

This phase 2 study looked at the effect on survival [...]

Read More

Comments Off on Nivolumab plus ipilimumab for advanced kidney cancer after progression on immunotherapy

• 

Ipilimumab-nivolumab and axitinib-pembrolizumab combinations produce similar survival times

By Sharon Deveson Kell|2022-10-27T08:20:36+00:0027 Oct 2022|Drug treatments|

When ipilimumab plus nivolumab or axitinib plus pembrolizumab are used [...]

Read More

Comments Off on Ipilimumab-nivolumab and axitinib-pembrolizumab combinations produce similar survival times

• 

A modified nivolumab/ipilimumab dosing regimen

By Sharon Deveson Kell|2022-10-03T09:29:48+00:003 Oct 2022|Drug treatments|

In this phase 3b/4 study, people with advanced kidney cancer [...]

Read More

Comments Off on A modified nivolumab/ipilimumab dosing regimen

• 

ESMO 2022: Nivolumab before and after surgery to prevent recurrence of kidney cancer

By Sharon Deveson Kell|2022-09-14T08:05:41+00:0012 Sep 2022|Drug treatments|

In this phase 3 randomised study, presented at the European [...]

Read More

Comments Off on ESMO 2022: Nivolumab before and after surgery to prevent recurrence of kidney cancer

• 

ESMO 2022: Combination of cabozantinib, nivolumab and ipilimumab for patients with advanced kidney cancer with high-risk disease

By Sharon Deveson Kell|2022-09-14T08:26:50+00:009 Sep 2022|Drug treatments|

The results of COSMIC-131 were presented at the European Society [...]

Read More

Comments Off on ESMO 2022: Combination of cabozantinib, nivolumab and ipilimumab for patients with advanced kidney cancer with high-risk disease